MNMD
Definium Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$20.69
+0.44%Sep 15, 2026, 12:45 UTC
The U.S. Food and Drug Administration held a public hearing on September 14 on how psychedelic drugs might be used as supervised treatments, with public comments open until October 5.
Source:Sep 14, 2026, 11:00 UTC
Definium Therapeutics reported that its LSD-based therapy DT120 eased anxiety in a second late-stage trial, with patients on a 100-microgram dose showing a 9.8-point drop on the Hamilton Anxiety Rating Scale versus a 4.7-point drop for placebo.
Source:Sep 10, 2026, 11:00 UTC
Definium Therapeutics announced six poster presentations at Psych Congress 2026, taking place September 15-19 in New Orleans, covering topline Phase 3 data from the Emerge and Voyage trials of DT120 Orally Disintegrating Tablet in major depressive disorder and generalized anxiety disorder.
Source:Aug 17, 2026, 20:01 UTC
Definium Therapeutics issued inducement stock options to two newly hired non-executive employees to purchase an aggregate of 32,900 common shares, with effective grant dates of August 17, 2026.
Source:Aug 12, 2026, 12:01 UTC
Definium Therapeutics announced that its LSD therapy DT120 significantly eased anxiety in a late-stage Phase 3 trial for generalized anxiety disorder.
Aug 12, 2026, 11:36 UTC
DEFINIUM THERAPEUTICS shares resumed trading and surged 24% after positive data.
Source:Aug 6, 2026, 20:01 UTC
Definium Therapeutics reported its financial results for the quarter ended June 30, 2026.
Source:Jun 24, 2026, 00:00 UTC
Definium Therapeutics, Inc. signed an underwriting agreement for an underwritten public offering of 20,588,236 common shares at $34.00 per share, with expected gross proceeds of approximately $805 million, expected to close June 25, 2026.
Jun 22, 2026, 17:23 UTC
Definium Therapeutics Inc. shares surged as much as 60% on Monday after positive late-stage trial data for its experimental depression drug.